JP2024502466A - 抗発作治療薬の急速な送達のための方法および組成物 - Google Patents

抗発作治療薬の急速な送達のための方法および組成物 Download PDF

Info

Publication number
JP2024502466A
JP2024502466A JP2023541507A JP2023541507A JP2024502466A JP 2024502466 A JP2024502466 A JP 2024502466A JP 2023541507 A JP2023541507 A JP 2023541507A JP 2023541507 A JP2023541507 A JP 2023541507A JP 2024502466 A JP2024502466 A JP 2024502466A
Authority
JP
Japan
Prior art keywords
diazepam
seizure
subject
composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502466A5 (https=
JPWO2022150540A5 (https=
Inventor
ミスラ、スニータ
カラザナ、エンリケ、ジェイ．
ラビノウィッツ、エイドリアン、エル．
マデン、スチュアート
マジオ、エドワード、ティー．
マイケル ガスティン、リチャード
Original Assignee
ニューレリス、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューレリス、インク． filed Critical ニューレリス、インク．
Publication of JP2024502466A publication Critical patent/JP2024502466A/ja
Publication of JP2024502466A5 publication Critical patent/JP2024502466A5/ja
Publication of JPWO2022150540A5 publication Critical patent/JPWO2022150540A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
  • Rolling Contact Bearings (AREA)
JP2023541507A 2021-01-08 2022-01-07 抗発作治療薬の急速な送達のための方法および組成物 Pending JP2024502466A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163135291P 2021-01-08 2021-01-08
US63/135,291 2021-01-08
US202163276761P 2021-11-08 2021-11-08
US202163276760P 2021-11-08 2021-11-08
US63/276,761 2021-11-08
US63/276,760 2021-11-08
US202163284033P 2021-11-30 2021-11-30
US63/284,033 2021-11-30
PCT/US2022/011538 WO2022150540A1 (en) 2021-01-08 2022-01-07 Methods and compositions for rapid delivery of anti-seizure therapeutics

Publications (3)

Publication Number Publication Date
JP2024502466A true JP2024502466A (ja) 2024-01-19
JP2024502466A5 JP2024502466A5 (https=) 2025-01-15
JPWO2022150540A5 JPWO2022150540A5 (https=) 2025-01-15

Family

ID=82323232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541507A Pending JP2024502466A (ja) 2021-01-08 2022-01-07 抗発作治療薬の急速な送達のための方法および組成物

Country Status (6)

Country Link
US (2) US20220218598A1 (https=)
EP (1) EP4274618A4 (https=)
JP (1) JP2024502466A (https=)
KR (1) KR20230144019A (https=)
AU (1) AU2022206421A1 (https=)
WO (1) WO2022150540A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117580579A (zh) * 2021-06-10 2024-02-20 纽瑞莱斯有限公司 用于治疗儿科患者的癫痫发作病症的方法和组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014519525A (ja) * 2011-06-14 2014-08-14 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
CA2756690C (en) * 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
EP2694076A4 (en) * 2011-04-01 2014-08-27 Cpex Pharmaceuticals Inc Nasal formulations of benzodiazepine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014519525A (ja) * 2011-06-14 2014-08-14 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EPILEPSIA, vol. Volume 55, Issue 10, JPN6025053710, 2014, pages 1544 - 1550, ISSN: 0005763331 *
EPILEPSIA, vol. Volume 61, Issue 5, JPN6025053709, 2020, pages 935 - 943, ISSN: 0005763332 *

Also Published As

Publication number Publication date
AU2022206421A1 (en) 2023-07-13
WO2022150540A1 (en) 2022-07-14
WO2022150540A9 (en) 2022-10-13
US20240299290A1 (en) 2024-09-12
US20220218598A1 (en) 2022-07-14
EP4274618A4 (en) 2025-04-23
EP4274618A1 (en) 2023-11-15
KR20230144019A (ko) 2023-10-13

Similar Documents

Publication Publication Date Title
KR100891568B1 (ko) 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법
WALBURGA et al. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients
Gillin et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
KR20170048567A (ko) 신경활성 스테로이드, 그의 조성물, 및 용도
EA002554B1 (ru) Применение кабэрголина при лечении синдрома усталых ног
KR20220167315A (ko) Lsd 용량 확인
KR20150096370A (ko) 항불안제 조성물, 제형 및 사용방법
WO2002078629A2 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
TWI549678B (zh) ４－胺基吡啶於改善具有脫髓鞘及其他神經系統狀況之患者的神經認知及／或神經精神缺陷之用途
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
KR20210149028A (ko) 우울증의 치료 방법
CN109069518B (zh) 睾酮制剂以及用其治疗的方法
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
Egeberg et al. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances
Feng et al. Transcutaneous electrical acupoint stimulation as an adjunct therapy for obsessive-compulsive disorder: A randomized controlled study
US20240299290A1 (en) Methods and compositions for rapid delivery of anti-seizure therapeutics
US12599611B2 (en) Methods and compositions for treating seizure disorders in pediatric patients
US20060084659A1 (en) Augmentation of psychotherapy with cannabinoid reuptake inhibitors
WO2010036977A2 (en) Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
US20200038420A1 (en) Aminosterol compositions and methods of using the same for treating depression
Nikova et al. Which is the Prognostic Value of the Mini Mental State Examination Test in Surgical Oncology?
Tsiouris Psychotropic medications
US9211311B2 (en) Methods for the treatment of neurodegenerative disorders
WO2024211216A1 (en) Cilnidipine and a p-glycoprotein inhibitor for treating pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250103

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260403